JP2007509978A - トコフェロール修飾治療薬化合物 - Google Patents

トコフェロール修飾治療薬化合物 Download PDF

Info

Publication number
JP2007509978A
JP2007509978A JP2006538354A JP2006538354A JP2007509978A JP 2007509978 A JP2007509978 A JP 2007509978A JP 2006538354 A JP2006538354 A JP 2006538354A JP 2006538354 A JP2006538354 A JP 2006538354A JP 2007509978 A JP2007509978 A JP 2007509978A
Authority
JP
Japan
Prior art keywords
moiety
compound
tocopherol
therapeutic
camptothecin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006538354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509978A5 (enExample
Inventor
ユエフア チャン，
リン シー． ゴールド，
Original Assignee
ソーナス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソーナス ファーマシューティカルズ， インコーポレイテッド filed Critical ソーナス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2007509978A publication Critical patent/JP2007509978A/ja
Publication of JP2007509978A5 publication Critical patent/JP2007509978A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006538354A 2003-10-29 2004-10-29 トコフェロール修飾治療薬化合物 Pending JP2007509978A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51536403P 2003-10-29 2003-10-29
US55613704P 2004-03-24 2004-03-24
US55876204P 2004-04-01 2004-04-01
US62165504P 2004-10-26 2004-10-26
PCT/US2004/036127 WO2005042539A1 (en) 2003-10-29 2004-10-29 Tocopherol-modified therapeutic drug compounds

Publications (2)

Publication Number Publication Date
JP2007509978A true JP2007509978A (ja) 2007-04-19
JP2007509978A5 JP2007509978A5 (enExample) 2007-12-13

Family

ID=34557676

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538354A Pending JP2007509978A (ja) 2003-10-29 2004-10-29 トコフェロール修飾治療薬化合物

Country Status (12)

Country Link
US (3) US7223770B2 (enExample)
EP (1) EP1682552B1 (enExample)
JP (1) JP2007509978A (enExample)
KR (1) KR20060110872A (enExample)
AT (1) ATE472551T1 (enExample)
AU (1) AU2004285037B2 (enExample)
BR (1) BRPI0415858A (enExample)
CA (1) CA2543722C (enExample)
DE (1) DE602004027936D1 (enExample)
IL (1) IL175158A0 (enExample)
TW (1) TW200522978A (enExample)
WO (1) WO2005042539A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504937A (ja) * 2007-11-28 2011-02-17 セレーター ファーマスーティカルズ、インク． 改良されたタキサン送達システム
JP2014532733A (ja) * 2011-11-11 2014-12-08 チア タイ ティアンチン ファーマシューティカル グループ カンパニー リミテッド トロロックス誘導体修飾脂溶性抗がん剤化合物、ならびにその製剤、製造方法および使用
JP2017530976A (ja) * 2014-10-08 2017-10-19 エピジェネティクス・ファーマ・エルエルシー ビタミンｅ−ヌクレオシド・プロドラッグ
JP2018513130A (ja) * 2015-04-27 2018-05-24 中国医学科学院基礎医学研究所 Ｈｓｐ９０阻害ペプチド結合体及びその腫瘍治療における応用
JP2022528298A (ja) * 2018-12-07 2022-06-10 オックスフォード ユニバーシティ イノベーション リミテッド リンカー
US12268749B2 (en) 2018-08-09 2025-04-08 Oxford University Innovation Limited Cell-penetrating peptides
US12472264B2 (en) 2018-08-09 2025-11-18 Oxford University Innovation Limited Cell-penetrating peptides
US12583889B2 (en) 2017-02-17 2026-03-24 Oxford University Innovation Limited Cell penetrating peptides

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
ES2391775T3 (es) * 2004-11-05 2012-11-29 Samyang Biopharmaceuticals Corporation Formulación farmacéutica para aumentar la solubilidad de compuestos de 10-hidroxicamptotecina en disolventes polares no acuosos
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
NZ595313A (en) 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
AU2016244292A1 (en) * 2005-07-18 2016-11-03 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
JP5368793B2 (ja) 2005-07-18 2013-12-18 ユニバーシティ オブ マサチューセッツ ロウエル ナノエマルジョンを製造および使用するための組成物および方法
WO2007035311A2 (en) * 2005-09-16 2007-03-29 University Of Massachusetts Lowell Anti-oxidant synergy formulation nanoemulsions to treat cancer
US7572610B2 (en) * 2005-10-03 2009-08-11 Biotechnology Research & Development Corporation Methods of making compositions comprising a UV-Absorbing chromophore
US7727514B2 (en) * 2005-10-03 2010-06-01 Biotechnology Research & Development Corporation Compositions comprising a UV-absorbing chromophore
US7744856B2 (en) * 2005-10-03 2010-06-29 Biotech Research And Development Corporation Formulations with feruloyl glycerides and methods of preparation
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
PT3144013T (pt) 2005-12-01 2019-02-07 Univ Massachusetts Lowell Nanoemulsões botulínicas
US7786134B2 (en) * 2005-12-16 2010-08-31 Sonus Pharmaceuticals, Inc. Lipophilic anticancer drug compounds, compositions and related methods
CZ300305B6 (cs) * 2005-12-20 2009-04-15 Heaton, A. S. Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2008003090A2 (en) * 2006-06-29 2008-01-03 Biotech Research And Development Corporation Formulations with feruloyl glycerides and methods of preparation
WO2008016664A2 (en) * 2006-08-02 2008-02-07 University Of Massachusetts Lowell Compositions and methods for treating cancer with dacarbazine nanoemulsions
AU2007353340A1 (en) 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor
WO2008070538A2 (en) 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
CA2688415C (en) 2007-05-31 2015-11-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
CA2686225A1 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without tween 80
BRPI0909185A2 (pt) * 2008-03-20 2015-08-25 Virun Inc Derivado de vitamina e e seus usos
BRPI0909187A2 (pt) 2008-03-20 2015-08-04 Virun Inc Emulsões incluindo tocoferol de derivados de peg
US7670894B2 (en) * 2008-04-30 2010-03-02 Intel Corporation Selective high-k dielectric film deposition for semiconductor device
US20110212157A1 (en) * 2008-06-26 2011-09-01 Anterios, Inc. Dermal delivery
WO2010124223A1 (en) * 2009-04-23 2010-10-28 First Tech International Limited Anti-cancer tocotrienol analogues and associated methods
EP2473044B1 (en) * 2009-09-01 2014-04-02 First Tech International Limited Tocotrienol compositions
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
WO2011097481A1 (en) * 2010-02-05 2011-08-11 First Tech International Limited Tocotrienol esters
US20110200645A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Free Fatty Acid Emulsions
KR101622441B1 (ko) * 2010-03-23 2016-05-18 버런, 아이엔씨. 자당 지방산 에스테르를 포함하는 나노에멀전
BR112012024590A2 (pt) 2010-03-29 2016-05-31 Abraxis Bioscience Inc métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
JP6257324B2 (ja) 2010-06-04 2018-01-10 アブラクシス バイオサイエンス， エルエルシー 膵臓がんの処置方法
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
US9731025B2 (en) 2010-08-20 2017-08-15 National University Corporation Tokyo Medical And Dental University Pharmaceutical composition for transcolonic absorption
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
EP2811847B1 (en) 2012-02-10 2017-12-13 Virun, Inc. Beverage compositions containing non-polar compounds
CN102731519B (zh) * 2012-06-26 2014-12-17 济南精合医药科技有限公司 用于抗肿瘤药物的对硝基芳甲氧基喜树碱缺氧激活前药
CN102731518B (zh) * 2012-06-26 2014-12-03 济南精合医药科技有限公司 用于抗肿瘤药物的邻硝基芳甲氧基喜树碱缺氧激活前药
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
US20140314672A1 (en) * 2013-04-06 2014-10-23 Igdrasol, Inc. Nanoparticle therapeutic agents, their formulations, and methods of their use
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
WO2015171516A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
WO2015171924A2 (en) * 2014-05-07 2015-11-12 Cornell University Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
CN107074884A (zh) 2014-06-18 2017-08-18 西蒂斯制药有限责任公司 活性剂的矿物质氨基酸复合物
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
CN105777770B (zh) * 2014-12-26 2018-05-25 中国人民解放军第二军医大学 一种饱和长链脂肪酸修饰的7-乙基-10-羟基喜树碱化合物及其长循环脂质体
GB2550346B (en) * 2016-05-13 2021-02-24 Phytoceutical Ltd Micelles
JP6906047B2 (ja) 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
CN110225975A (zh) 2016-08-23 2019-09-10 阿库斯股份有限公司 用于治疗人受试者中非年龄相关的听力损害的组合物和方法
JP2019535829A (ja) 2016-11-21 2019-12-12 エイリオン セラピューティクス， インコーポレイテッド 大型薬剤の経皮送達
EA202190799A1 (ru) * 2018-09-17 2021-06-22 Дзе Чилдрен'З Хоспитал Оф Филадельфия Макромолекулярные пролекарства на полимерной основе
EP4114958A1 (en) 2020-02-21 2023-01-11 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
CA3229030A1 (en) * 2021-09-05 2023-03-09 Yi-Wen Chu Formulations with enhanced sn-38 solubility and oral absorption
MX2024003496A (es) 2021-10-15 2024-04-05 Kunshan Xinyunda Biotech Co Ltd Composicion que contiene un farmaco antitumoral, metodo de preparacion y uso de este.

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5484034A (en) * 1977-12-16 1979-07-04 Nisshin Flour Milling Co Ltd Anti-tumor agent
WO1997044026A1 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
WO1997044336A1 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Conjugates of cis-docosahexaenoic acid and paclitaxel
WO1999004787A1 (en) * 1997-07-26 1999-02-04 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Taxol emulsion
WO2000071163A1 (en) * 1999-05-24 2000-11-30 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
WO2002083067A2 (en) * 2001-04-17 2002-10-24 Cryolife, Inc. Prodrugs via acylation with cinnamate
JP2003512416A (ja) * 1999-10-25 2003-04-02 スーパージェン インコーポレイテッド パクリタクセル用の新規且つ改善された組成物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1395994A (en) * 1972-08-23 1975-05-29 Delmar Chem Tocopherol derivative processes for making it and pharmaceutical compositions containing it
GB1409612A (en) * 1973-09-13 1975-10-08 Ahrens G W Phenylpropyl-d-alpha-tocopherol-succinate the method for making the same and preparations
WO1979000401A1 (fr) * 1977-12-16 1979-07-12 Nisshin Flour Milling Co Agent anti-tumeur
US4665204A (en) * 1985-06-27 1987-05-12 Henkel Corporation Diester derivatives of tocopherol
US5610180A (en) * 1988-01-29 1997-03-11 Virginia Commonwealth University Ionizable congeners of aromatic and aliphatic alcohols as anti-leukemia agents
US5234695A (en) * 1990-07-24 1993-08-10 Eastman Kodak Company Water dispersible vitamin E composition
WO1995011039A1 (de) 1993-10-22 1995-04-27 Hexal Pharma Gmbh Pharmazeutische zusammensetzung mit cyclosporin a und alpha-tocopherol
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
CA2148148A1 (en) * 1994-05-20 1995-11-21 Kazumi Ogata Tocopherol derivatives
DE4423915A1 (de) * 1994-07-07 1996-01-11 Carl Heinrich Dr Weischer Derivate des Salazosulfapyridins, deren Herstellung und Verwendung als Arzneimittel
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US5945409A (en) * 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
US5912078A (en) * 1996-05-02 1999-06-15 Milliken & Company Lubricant finish for textiles
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6258823B1 (en) * 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US6545125B1 (en) * 1997-11-18 2003-04-08 Chugai Seiyaku Kabushiki Kaisha Compounds with antitumor activity
US5917060A (en) * 1997-12-17 1999-06-29 Basf Aktiengesellschaft Preparation of chromanyl derivatives
US6387882B1 (en) * 1997-12-24 2002-05-14 Senju Pharmaceutical Co., Ltd. Vitamin E derivatives
US6086915A (en) * 1998-04-01 2000-07-11 Bioresponse L.L.C. Compositions and methods of adjusting steroid hormone metabolism through phytochemicals
EP1115398B1 (en) * 1998-09-23 2010-05-05 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6045826A (en) * 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
CA2394645A1 (en) * 1999-06-11 2000-12-21 Sydney Hyman Image making medium
AU7719100A (en) * 1999-09-27 2001-04-30 Panayiotis Constantinides Compositions of tocol-soluble therapeutics
WO2002076970A2 (en) * 2001-03-23 2002-10-03 Sonus Pharmaceuticals, Inc. Tocopherol succinate derivatives and compositions
US6858227B1 (en) * 2001-11-21 2005-02-22 Sonus Pharmaceuticals, Inc. Vitamin E conjugates
US6683194B2 (en) * 2002-02-05 2004-01-27 Sonus Pharmaceuticals, Inc. Tocopherol derivatives

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5484034A (en) * 1977-12-16 1979-07-04 Nisshin Flour Milling Co Ltd Anti-tumor agent
WO1997044026A1 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
WO1997044336A1 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Conjugates of cis-docosahexaenoic acid and paclitaxel
WO1999004787A1 (en) * 1997-07-26 1999-02-04 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Taxol emulsion
WO2000071163A1 (en) * 1999-05-24 2000-11-30 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
JP2003512416A (ja) * 1999-10-25 2003-04-02 スーパージェン インコーポレイテッド パクリタクセル用の新規且つ改善された組成物
WO2002083067A2 (en) * 2001-04-17 2002-10-24 Cryolife, Inc. Prodrugs via acylation with cinnamate

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5006018350; ＡＮＳＥＬＬ　ＳＴＥＶＥＮ　Ｍ: ＡＢＳＴＲＡＣＴＳ　ＯＦ　ＰＡＰＥＲＳ　ＡＭＥＲＩＣＡＮ　ＣＨＥＭＩＣＡＬ　ＳＯＣＩＥＴＹ Ｖ２１２　Ｎ１-２, 1996, ＭＥＤＩ　０４８ *
JPN5006018351; ＬＩＵ　Ｘ: ＪＯＵＲＮＡＬ　ＯＦ　ＴＨＥ　ＡＭＥＲＩＣＡＮ　ＣＨＥＭＩＣＡＬ　ＳＯＣＩＥＴＹ Ｖ１２４　Ｎ２６, 2002, Ｐ７６５０-７６５１, ＡＭＥＲＩＣＡＮ　ＣＨＥＭＩＣＡＬ　ＳＯＣＩＥＴＹ *
JPN5006018352; ＤＡＬＬＡＶＡＬＬＥ　Ｓ: ＥＸＰＥＲＴ　ＯＰＩＮＩＯＮ　ＯＮ　ＴＨＥＲＡＰＥＵＴＩＣ　ＰＡＴＥＮＴＳ Ｖ１２　Ｎ６, 2002, Ｐ８３７-８４４, ＡＳＨＬＥＹ　ＰＵＢＬＩＣＡＴＩＯＮＳ *
JPN5006018353; ＬＵＮＤＢＥＲＧ　Ｂ　Ｂ: ＪＯＵＲＮＡＬ　ＯＦ　ＣＯＮＴＲＯＬＬＥＤ　ＲＥＬＥＡＳＥ Ｖ８６　Ｎ１, 20030109, Ｐ９３-１００, ＥＬＳＥＶＩＥＲ　ＳＣＩＥＮＣＥ　ＰＵＢＬＩＳＨＥＲＳ　Ｂ．Ｖ． *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504937A (ja) * 2007-11-28 2011-02-17 セレーター ファーマスーティカルズ、インク． 改良されたタキサン送達システム
US8486924B2 (en) 2007-11-28 2013-07-16 Celator Pharmaceuticals, Inc. Taxane delivery system
JP2014532733A (ja) * 2011-11-11 2014-12-08 チア タイ ティアンチン ファーマシューティカル グループ カンパニー リミテッド トロロックス誘導体修飾脂溶性抗がん剤化合物、ならびにその製剤、製造方法および使用
JP2017530976A (ja) * 2014-10-08 2017-10-19 エピジェネティクス・ファーマ・エルエルシー ビタミンｅ−ヌクレオシド・プロドラッグ
JP2018513130A (ja) * 2015-04-27 2018-05-24 中国医学科学院基礎医学研究所 Ｈｓｐ９０阻害ペプチド結合体及びその腫瘍治療における応用
US10918731B2 (en) 2015-04-27 2021-02-16 Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences HSP90 inhibitory peptide conjugate and application thereof in treating tumor
US12583889B2 (en) 2017-02-17 2026-03-24 Oxford University Innovation Limited Cell penetrating peptides
US12268749B2 (en) 2018-08-09 2025-04-08 Oxford University Innovation Limited Cell-penetrating peptides
US12472264B2 (en) 2018-08-09 2025-11-18 Oxford University Innovation Limited Cell-penetrating peptides
JP2022528298A (ja) * 2018-12-07 2022-06-10 オックスフォード ユニバーシティ イノベーション リミテッド リンカー
US12465646B2 (en) 2018-12-07 2025-11-11 Oxford University Innovation Limited Linkers

Also Published As

Publication number Publication date
BRPI0415858A (pt) 2007-01-09
EP1682552A1 (en) 2006-07-26
KR20060110872A (ko) 2006-10-25
US20050096340A1 (en) 2005-05-05
ATE472551T1 (de) 2010-07-15
US20060229359A1 (en) 2006-10-12
TW200522978A (en) 2005-07-16
CA2543722A1 (en) 2005-05-12
WO2005042539A1 (en) 2005-05-12
AU2004285037B2 (en) 2010-07-22
US7223770B2 (en) 2007-05-29
AU2004285037A1 (en) 2005-05-12
DE602004027936D1 (de) 2010-08-12
IL175158A0 (en) 2006-09-05
EP1682552B1 (en) 2010-06-30
CA2543722C (en) 2011-01-04
US20070207196A1 (en) 2007-09-06

Similar Documents

Publication Publication Date Title
JP2007509978A (ja) トコフェロール修飾治療薬化合物
US20080045559A1 (en) Tocopherol-modified therapeutic drug compounds
US20060003976A1 (en) Cholesterol/bile acid/bile acid derivative-modified therapeutic drug compounds
AU784395B2 (en) Taxane prodrugs
JP5369137B2 (ja) 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤
US10172795B2 (en) Formulations and carrier systems including compound interactive domains
JP4757633B2 (ja) 難水溶性抗癌剤と新規ブロック共重合体を含むミセル調製物
US7786164B2 (en) Lipophilic di(anticancer drug) compounds, compositions, and related methods
JP2011506276A (ja) 水溶解度の低い治療剤のナノ粒子
CN113264906A (zh) 多西他赛二聚体小分子前药及其自组装纳米粒的构建
US20040213757A1 (en) Water soluble wortmannin derivatives
JP2019512496A (ja) 抗がん効能を高めたオリゴ乳酸複合体及びミセル
US10406239B2 (en) Water-soluble docetaxel anticancer drug compound and preparation method and use thereof
CN102491981B (zh) 水溶性维生素e衍生物修饰的双亲性抗癌药物化合物和制剂、该化合物的制备方法及应用
CN1875022B (zh) 生育酚修饰的治疗性药物化合物
US7786134B2 (en) Lipophilic anticancer drug compounds, compositions and related methods
RU2340616C2 (ru) Токоферол-модифицированные терапевтические лекарственные соединения
EP2588081A1 (en) Oral formulation of kinase inhibitors
CN1743337B (zh) 一种紫杉醇衍生物及其药物组合物
MXPA06004429A (en) Tocopherol-modified therapeutic drug compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120925